27 Feb 2015

Thalidomide Celgene (Talidomide) - Italia

ATC: L04AX
ANTINEOPLASTIC AND IMMUNOMODULATING AGENTS
IMMUNOSUPPRESSANTS
IMMUNOSUPPRESSANTS
OTHER IMMUNOSUPPRESSANTS
Thalidomide Celgene

Last Updated on 27 Feb 2015 by EPG Health Media Staff

Suggest content to an epgonline.org editor - or let us know about a mistake you have spotted on this page

Thalidomide Celgene Indication

Thalidomide Celgene, in associazione a melfalan e prednisone, è indicata per il trattamento di prima linea di pazienti con mieloma multiplo non trattato di età ≥ 65 anni o non idonei a chemioterapia a dosi elevate.

Thalidomide Celgene viene prescritta e dispensata in conformità al Programma di Prevenzione della Gravidanza di Thalidomide Celgene.

 

Thalidomide Celgene Generic Name

Talidomide

Type

POM

Summary Product Characteristics (SPCs) Links
Riassunto delle Caratteristiche del Prodotto - Thalidomide Celgene (external site)

Related Learning Zones

Prostate Cancer Learning Hub

Prostate Cancer Learning Hub

The Prostate Cancer Learning Hub has been designed with the busy healthcare professional in mind. The resource conveniently organises a range of up-to-date education content, reference materials and decision support tools, all focussing on prostate cancer. The disease awareness section provides you with access to a Prostate Cancer Knowledge Centre, which has been developed to provide you with easy to digest best practice guidance for the treatment and management of patients with prostate cancer.

IL-17A in Psoriasis Knowledge Centre

IL-17A in Psoriasis Knowledge Centre

IL-17A in Psoriasis is intended for healthcare professionals involved in the treatment and management of patients with psoriasis. This resource has been developed primarily to discuss the role of the IL-17 pathway in the pathogenesis of psoriasis and the therapeutic potential of treatments directed towards IL-17A. Users can expect to find sections containing expert videos, clinical slide decks, congress highlights, key publications and links to useful resources.

This resource has been developed in collaboration with Novartis Pharma AG.

Selected content related to Thalidomide Celgene (Talidomide)

Guidelines

Thalidomide Celgene Marketing Information

Thalidomide Celgene Generic Name
Talidomide
Marketing Company
Celgene Europe Limited
Drug Type
POM
Date of Issue, Marketing Authority

16/04/2008

Related Drugs - Oncology

Back to top